{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T11:47:58Z","timestamp":1753876078166,"version":"3.41.2"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T00:00:00Z","timestamp":1743897600000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,3]]},"abstract":"<jats:title>Summary<\/jats:title>\n               <jats:p>Erosive esophagitis (EE) is a common complication of gastroesophageal reflux disease. Guidelines support long-term proton pump inhibitor (PPI) therapy to relieve symptoms and maintain healing of EE. Ideally, patients remain on their first line of therapy (LOT) with an effective PPI. We aimed to measure how often patients receive PPI, persistence and cycling among LOTs, and resulting healthcare resource utilization and costs. We assessed administrative claims data of patients diagnosed with EE between 01 October 2016 and 31 December 2020 using the Optum Research Database. We assessed prescribing rates of the first PPI, persistence, and rate of cycling among LOTs, health care resource utilization, and overall costs. Of 281,087 patients with EE, 178,789 had endoscopy. Overall, 27% of EE-diagnosed patients and 21% of patients in the endoscopy subgroup did not receive a PPI prescription. Among patients that did receive PPI, cycling and switching among PPIs was common, with over 50% of those patients switching to another PPI or back to a previously-used PPI after a lapse in therapy. Average total all-cause costs per patient among endoscopy patients (including patients with no record of PPI fills) were $58,692.46, and average total EE-related costs were $4304.88. Patients with EE frequently cycle and switch among PPIs. About one-fifth of patients who underwent endoscopy did not receive prescription PPI. Health care resource utilization and costs in patients with EE are substantial. PPI cycling and high discontinuation rates to PPI therapy contribute to costs associated with EE and potential delays in effective therapy.<\/jats:p>","DOI":"10.1093\/dote\/doaf026","type":"journal-article","created":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T19:44:16Z","timestamp":1743968656000},"source":"Crossref","is-referenced-by-count":0,"title":["Economic and treatment burden among newly diagnosed patients with erosive esophagitis in the US: a national retrospective cohort study"],"prefix":"10.1093","volume":"38","author":[{"given":"N J","family":"Shaheen","sequence":"first","affiliation":[{"name":"Department of Medicine, University of North Carolina at Chapel Hill , Chapel Hill, NC ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D A","family":"Patel","sequence":"additional","affiliation":[{"name":"Center for Esophageal Disorders, Division of Gastroenterology, Hepatology, and Nutrition, Vanderbilt University Medical Center , Nashville, TN ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I","family":"Abeynayake","sequence":"additional","affiliation":[{"name":"Research and Development, Phathom Pharmaceuticals Buffalo Grove , IL ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Bui","sequence":"additional","affiliation":[{"name":"Value and Evidence Solutions, Optum , Eden Prairie, MN ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Gopal","sequence":"additional","affiliation":[{"name":"Research and Development, Phathom Pharmaceuticals Buffalo Grove , IL ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Jacob","sequence":"additional","affiliation":[{"name":"Research and Development, Phathom Pharmaceuticals Buffalo Grove , IL ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Chastek","sequence":"additional","affiliation":[{"name":"Value and Evidence Solutions, Optum , Eden Prairie, MN ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Steiger","sequence":"additional","affiliation":[{"name":"Value and Evidence Solutions, Optum , Eden Prairie, MN ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E D","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Michigan , Ann Arbor, MI ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,4,6]]},"reference":[{"key":"2025070704513569500_ref1","doi-asserted-by":"crossref","first-page":"m3786","DOI":"10.1136\/bmj.m3786","article-title":"Advances in the diagnosis and management of gastroesophageal reflux disease","volume":"371","author":"Katzka","year":"2020","journal-title":"BMJ"},{"issue":"7","key":"2025070704513569500_ref2","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1136\/gutjnl-2017-314722","article-title":"Modern diagnosis of GERD: the Lyon consensus","volume":"67","author":"Gyawali","year":"2018","journal-title":"Gut"},{"issue":"1","key":"2025070704513569500_ref3","doi-asserted-by":"crossref","first-page":"5814","DOI":"10.1038\/s41598-020-62795-1","article-title":"Global prevalence and risk factors of gastro-oesophageal reflux disease (GORD): systematic review with meta-analysis","volume":"10","author":"Nirwan","year":"2020","journal-title":"Sci Rep"},{"issue":"11","key":"2025070704513569500_ref4","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1038\/ajg.2011.326","article-title":"Erosive esophagitis is a risk factor for Barrett's esophagus: a community-based endoscopic follow-up study","volume":"106","author":"Ronkainen","year":"2011","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"2025070704513569500_ref5","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/14656566.2020.1817385","article-title":"The pharmacotherapeutic management of gastroesophageal reflux disease (GERD)","volume":"22","author":"Chapelle","year":"2021","journal-title":"Expert Opin Pharmacother"},{"issue":"11","key":"2025070704513569500_ref6","first-page":"29","article-title":"How satisfied are chronic heartburn sufferers with their prescription medications? Results of the patient unmet needs survey","volume":"7","author":"Crawley","year":"2000","journal-title":"JCOM-WAYNE PA"},{"issue":"8","key":"2025070704513569500_ref7","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/17474124.2019.1645596","article-title":"New classifications of gastroesophageal reflux disease: an improvement for patient management?","volume":"13","author":"Ribolsi","year":"2019","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"4","key":"2025070704513569500_ref8","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/MOG.0b013e32833ae2be","article-title":"Management of gastroesophageal reflux disease that does not respond well to proton pump inhibitors","volume":"26","author":"Hershcovici","year":"2010","journal-title":"Curr Opin Gastroenterol"},{"issue":"8","key":"2025070704513569500_ref9","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1185\/03007990903035745","article-title":"Treatment patterns and symptom control in patients with GERD: US community-based survey","volume":"25","author":"Chey","year":"2009","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"2025070704513569500_ref10","doi-asserted-by":"crossref","first-page":"69","DOI":"10.5056\/jnm14078","article-title":"Predictive factors of response to proton pump inhibitors in korean patients with gastroesophageal reflux disease","volume":"21","author":"Kim","year":"2015","journal-title":"J Neurogastroenterol Motil"},{"issue":"3","key":"2025070704513569500_ref11","doi-asserted-by":"crossref","first-page":"309","DOI":"10.5056\/jnm15105","article-title":"Unmet needs in the treatment of gastroesophageal reflux disease","volume":"21","author":"Dickman","year":"2015","journal-title":"J Neurogastroenterol Motil"},{"issue":"6","key":"2025070704513569500_ref12","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1053\/gast.1997.v112.pm9178669","article-title":"Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis","volume":"112","author":"Chiba","year":"1997","journal-title":"Gastroenterology"},{"issue":"2","key":"2025070704513569500_ref13","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1046\/j.1365-2036.2001.00904.x","article-title":"Meta-analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis","volume":"15","author":"Sharma","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"2025070704513569500_ref14","doi-asserted-by":"crossref","first-page":"308-28","DOI":"10.1038\/ajg.2012.444","article-title":"Guidelines for the diagnosis and management of gastroesophageal reflux disease","volume":"108","author":"Katz","year":"2013","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"2025070704513569500_ref15","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1370\/afm.1364","article-title":"Association of patient-centered outcomes with patient-reported and ICD-9-based morbidity measures","volume":"10","author":"Bayliss","year":"2012","journal-title":"Ann Fam Med"},{"issue":"6","key":"2025070704513569500_ref16","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan","year":"2011","journal-title":"Am J Epidemiol"},{"year":"2017","author":"Cost","key":"2025070704513569500_ref17"},{"author":"Optum","key":"2025070704513569500_ref18"},{"issue":"1","key":"2025070704513569500_ref19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.14309\/ajg.0000000000001538","article-title":"ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease","volume":"117","author":"Katz","year":"2022","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"2025070704513569500_ref20","doi-asserted-by":"crossref","first-page":"5489","DOI":"10.1007\/s12325-023-02688-7","article-title":"A linked electronic medical record-claims analysis of the clinical and economic outcomes of patients coded for erosive esophagitis in the United States","volume":"40","author":"Yadlapati","year":"2023","journal-title":"Adv Ther"},{"issue":"1","key":"2025070704513569500_ref21","doi-asserted-by":"publisher","first-page":"e000941","DOI":"10.1136\/bmjgast-2022-000941","article-title":"Patient journey in erosive oesophagitis: real-world perspectives from US physicians and patients","volume":"9","author":"Vaezi","year":"2022","journal-title":"BMJ Open Gastroenterol"},{"issue":"1","key":"2025070704513569500_ref22","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1053\/j.ajkd.2009.11.019","article-title":"A case series of proton pump inhibitor-induced hypomagnesemia","volume":"56","author":"Hoorn","year":"2010","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"2025070704513569500_ref23","doi-asserted-by":"crossref","first-page":"391","DOI":"10.7326\/0003-4819-149-6-200809160-00005","article-title":"Proton-pump inhibitor use and the risk for community-acquired pneumonia","volume":"149","author":"Sarkar","year":"2008","journal-title":"Ann Intern Med"},{"issue":"4","key":"2025070704513569500_ref24","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/ajg.2018.29","article-title":"Discontinuing long-term PPI therapy: why, with whom, and how?","volume":"113","author":"Targownik","year":"2018","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"2025070704513569500_ref25","doi-asserted-by":"crossref","first-page":"689","DOI":"10.14309\/ajg.0000000000000558","article-title":"Physicians\u2019 perceptions of proton pump inhibitor risks and recommendations to discontinue: a National Survey","volume":"115","author":"Kurlander","year":"2020","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"2025070704513569500_ref26","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1053\/j.gastro.2018.08.063","article-title":"Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2018","volume":"156","author":"Peery","year":"2019","journal-title":"Gastroenterology"},{"issue":"21","key":"2025070704513569500_ref27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20215469","article-title":"Problems associated with deprescribing of proton pump inhibitors","volume":"20","author":"Helgadottir","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2025070704513569500_ref28","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1016\/j.cgh.2023.08.026","article-title":"Optimizing the management algorithm for heartburn in general gastroenterology: cost-effectiveness and cost-minimization analysis","volume":"22","author":"Shah","year":"2024","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Diseases of the Esophagus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/dote\/article-pdf\/38\/2\/doaf026\/62874683\/doaf026.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/dote\/article-pdf\/38\/2\/doaf026\/62874683\/doaf026.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T08:51:44Z","timestamp":1751878304000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/dote\/article\/doi\/10.1093\/dote\/doaf026\/8106810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,3]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3,3]]}},"URL":"https:\/\/doi.org\/10.1093\/dote\/doaf026","relation":{},"ISSN":["1120-8694","1442-2050"],"issn-type":[{"type":"print","value":"1120-8694"},{"type":"electronic","value":"1442-2050"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2025,3,3]]},"article-number":"doaf026"}}